Among them, C17 exhibited a stronger and dose-dependent inhibitory effect on patient-derived glioblastoma stem cells in a PUS7-dependent manner in vitro and that it preferentially targets glioblastoma stem cells compared to neural stem cells. Here, PUS7 is linked to glioblastoma.